Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668634 | 0.86 | HRH3 (0.42) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL25704492 | 0.85 | PIK3CD (0.40) | HRH3SLC6A9SMN1; SMN2KMT2A | |
| SCHEMBL23312132 | 0.81 | SLC6A9 (0.31) | HRH3SLC6A9SMN1; SMN2MEN1ALDH1A1 | |
| SCHEMBL29115965 | 0.80 | CHRM1 (0.31) | SLC6A9CHRM1 | |
| SCHEMBL23876808 | 0.80 | MEN1 (0.36) | HRH3SLC6A9MEN1KMT2AEGLN1 | |
| SCHEMBL20314879 | 0.80 | JAK3 (0.38) | — | |
| SCHEMBL23569900 | 0.80 | JAK3 (0.38) | — | |
| SCHEMBL23133923 | 0.80 | MEN1 (0.36) | HRH3SLC6A9MEN1KMT2AEGLN1 | |
| SCHEMBL23308415 | 0.80 | JAK3 (0.38) | — | |
| SCHEMBL3867178 | 0.79 | ALDH1A1 (0.50) | HRH3SMN1; SMN2MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | HRH3 4690/4885SLC6A9 4485/4885CHRM1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.